BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » iPSCs

How iPSCs are Becoming an Emerging Area of Stem Cell Research

April 11, 2018 By Cade Hildreth (CEO) Leave a Comment

How iPS Cells are becoming an Emerging Area of Stem Cell Research - Depositphotos_102309082_m-2015

Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and diverse market for iPSC research tools has emerged. Included below is a ten-year history of iPSC grants (source: RePORT.NIH.gov), clinical trials (source: ClinicalTrials.gov), and scientific publications (source: PubMed.gov).

Both graphs below reveal the iPSC market is expanding. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: Cellular Dynamics International, Coriell Institute for Medical Research, iPSCs, regenerative medicine, ReproCELL, stem cells

Cellectricon and Censo Launch Human iPSC-based Discovery Services for CNS and Pain Research

January 26, 2017 By Cade Hildreth (CEO) Leave a Comment

Cellectricon and Censo Biotechnologies

Cellectricon and Censo Biotechnologies Introduce a Joint Technology Access Program

High-quality Human iPSC-based discovery services for CNS and pain research.

Censo Biotechnologies and Cellectricon AB | January 26, 2017 – Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research. [Read more…]

Filed Under: iPS Cells Tagged With: Cellectricon AB, Censo Biotechnologies, chronic pain, iPSCs

Roslin Stem Cell Companies Combine to Create Censo Biotechnologies Group

May 10, 2016 By Cade Hildreth (CEO) Leave a Comment

Roslin Stem Cell Companies Combine to Create Censo Biotechnologies Group - Depositphotos_26533545_m-2015.jpg

Edinburgh, UK. 10 May 2016 — The merger was announced today of Roslin Cell Sciences and Roslin Cellab, two companies previously created as spin outs from the Roslin Institute and both focused on using stem cells to discover new drugs. Following the merger, the parent company has been renamed Censo Biotechnologies Ltd with Roslin Cell Sciences Ltd continuing to trade as a wholly owned subsidiary.

Censo Biotechnologies has extensive capacity to create and use induced Pluripotent Stem Cells (iPSCs) for drug discovery research with sites in Edinburgh and Cambridge, UK. The Company uses this capacity to produce stem cells from large diverse groups of individuals, so that drug development companies can understand how the efficacy of their drugs varies across the population. This underpins faster drug development and enables the right drug to be targeted to the right patient. [Read more…]

Filed Under: Stem Cells Tagged With: Censo Biotechnologies, drug discovery, iPSCs, merger, Roslin Cell Sciences, Roslin Cellab, Roslin Institute, stem cells

Axiogenesis Secures Funding for Market Expansion from Sino-German High-Tech Fund

May 3, 2016 By Cade Hildreth (CEO) 1 Comment

Axiogenesis Secures Major Funding for its Expansion Course - Depositphotos_7461269_m-2015

Founded in 2001 and headquartered in Cologne, Germany, Axiogensis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. The company also has an American subsidiary that was founded in 2014 and is located in Philadelphia, Pennsylvania. Since its launch, the company has grown into a market leader for in vitro models of healthy and diseased cell types and tissue. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: Axiogenesis, biotechnology, Donghai Securities, funding, iPSCs

STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids
(‘Mini Brains’) for Researchers

April 15, 2016 By Cade Hildreth (CEO) Leave a Comment

STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids for Researchers

In major news released today, STEMCELL Technologies announced that it has partnered with the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria, to develop products for cerebral organoid culture for researchers worldwide.

Founded in 1993 and headquartered in Vancouver, Canada, STEMCELL Technologies is a diversified provider of stem cell research products. The company is known for utilizing strategic alliances to grow its dominance within the stem cell field. Current partnerships of STEMCELL Technologies include a licensing deal with the Wisconsin Alumni Research Foundation (WARF), iPS Academia Japan Inc., Salk Institute for Biological Sciences, and more.

To learn more, read the full press release released by STEMCELL Technologies, printed with permission from Sam Lloyd-Burton, Senior Product Marketing Manager, Neural and Pluripotent Stem Cell Biology, at STEMCELL Technologies.

[Read more…]

Filed Under: iPS Cells, Neural Stem Cells, Stem Cells Tagged With: iPSCs, neural stem cells, press release, STEMCELL Technologies

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.